Hutch News

Hutch News

Stories tagged 'Matthias Stephan'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Nov. 21, 2016

Good News: Ceballos honored for public health research; ACS research awards to three Hutch scientists; ASH grant to physician-researcher Halpern; Paulovich facilitates Moonshot panel

View story >


How research and industry partnerships can advance cancer care

Fred Hutch, Merck co-host inaugural ‘Oncology Summit’ to capture non-profit and for-profit outlooks on cancer care

Sept. 27, 2016 | By Rachel Tompa / Fred Hutch News Service

Inaugural 'Oncology Summit,' co-hosted by Fred Hutch and Merck, allowed investors, key players in life sciences to collaborate and share scientific stories.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

July 14, 2016

Dr. Matthias Stephan awarded for immunotherapy work; Dr. Melinda Miernacki gets grant; Dr. Jesse Bloom honored by American Society for Virology

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

April 21, 2016

Women’s Health Initiative receives AACR Team Science Award; Andrew Hsieh awarded AACR NextGen Grant for Transformative Cancer Research; Designing an off-the-shelf nanoparticle-based immunotherapy; Fred Hutch’s Vaccine and Infectious Disease Division contributes to early study of promising Ebola vaccine

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Nov. 19, 2015 | By Fred Hutch News Service staff

More than a dozen Fred Hutch scientists and staff participated in the ninth annual Life Sciences Research Weekend Nov. 6-8 at Pacific Science Center in Seattle. Read about this and more Good News at Fred Hutch.

View story >


The right tools for the job: taking immunotherapy to the next level

Dr. Matthias Stephan is combining the fields of immunology, bioengineering and gene therapy to harness the immune system to treat solid tumors

May 22, 2015 | By Dr. Sabrina Richards / Fred Hutch News Service

Dr. Matthias Stephan is a pioneer in the field of immunobioengineering, working where “materials science meets immunology” to create unconventional solutions to treating cancer. He is devising inventive strategies to circumvent the hurdles that prevent immunotherapy from being cost-effective, widely available and effective against many types of cancer.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.